Metabolic modulation in heart failure: High time for a definitive clinical trial

Heart

Volumn 97, Issue 4, 2011, Pages 267-268

  Ashrafian, Houman ^a   Neubauer, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PERHEXILINE; RANOLAZINE; TRIMETAZIDINE;

CLINICAL TRIAL (TOPIC); EDITORIAL; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; META ANALYSIS (TOPIC); METABOLISM; MODULATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC HEART FAILURE;

ACETYL-COA C-ACYLTRANSFERASE; CHRONIC DISEASE; ENZYME INHIBITORS; HEART FAILURE; HUMANS; META-ANALYSIS AS TOPIC; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 79551494641     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.214932     Document Type: Editorial

References (15)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215.
2. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007;356:1140-51. (Pubitemid 46425598)
3. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-48.
4. Gao D, Ning N, Xiaolin N, et al. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart 2011;97:278-86.
5. Egger M, Smith GD. Misleading meta-analysis. BMJ 1995;310:752-4.
6. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250-8.
7. 2 and free fatty acids. Cardiovasc Res 1972;6:23-7.
8. Opie LH, Thandroyen FT, Muller C, et al. Adrenaline-induced "oxygen-wastage" and enzyme release from working rat heart. Effects of calcium antagonism, [beta]-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol 1979;11:1073-94. (Pubitemid 10165487)
9. Chess DJ, Khairallah RJ, O'Shea KM, et al. A high-fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload. Am J Physiol Heart Circ Physiol 2009;297:H1585-93.
10. Christopher BA, Huang HM, Berthiaume JM, et al. Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am J Physiol Heart Circ Physiol 2010;299:1917-27.
11. Yan J, Young ME, Cui L, et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009;119:2818-28.
12. Sutendra G, Bonnet S, Rochefort G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2010;2:44ra58.
13. Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010;122:1562-9.
14. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
15. Tang WH. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice. J Am Coll Cardiol 2006;48:999-1000.